(AVXL) Anavex Life Sciences - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 281m USD | Total Return: -67% in 12m
Avg Turnover: 3.32M
Qual. Beats: 3
Qual. Beats: 0
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Anavex Life Sciences Corp. (AVXL) is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) disorders and rare diseases. The company’s primary focus is on restoring cellular homeostasis through the activation of the sigma-1 receptor (SIGMAR1), a protein chaperone that regulates cellular functions often disrupted in neurodegenerative conditions.
The lead product candidate, blarcamesine (ANAVEX 2-73), is an orally administered small molecule currently being evaluated for Alzheimer’s disease, Parkinson’s disease dementia, and Rett syndrome. Biotechnology firms operating in the CNS sector face high regulatory hurdles and significant R&D costs, as clinical trials for neurodegenerative diseases typically require long-term observation to prove efficacy in slowing disease progression.
The company is also advancing ANAVEX 3-71, a dual SIGMAR1 and M1 muscarinic receptor agonist intended to address cognitive deficits and protein pathologies. Evaluating the clinical pipeline and historical trial data on ValueRay can provide deeper context for these developmental milestones. Headquartered in New York, Anavex utilizes a business model centered on proprietary drug discovery and the pursuit of regulatory approvals for high-unmet-need medical conditions.
- FDA marketing application timeline for blarcamesine in Alzheimer’s treatment
- Rett syndrome clinical data results influence future regulatory approval pathways
- Pipeline expansion into Parkinson’s disease and schizophrenia drives long-term valuation
- Cash burn rates and potential equity dilution impact near-term share price
- EMA regulatory feedback on pediatric Rett syndrome trials dictates international expansion
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.26 > 0.02 and ΔFCF/TA 3.09 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.26 > 3% & CFO -34.1m > Net Income -39.9m |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: 20.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (89.0m) vs 12m ago 4.98% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.95 (Total Current Assets 133.0m - Total Current Liabilities 6.37m) / Total Assets 133.0m |
| B: -2.92 (Retained Earnings -388.1m / Total Assets 133.0m) |
| C: -0.35 (EBIT TTM -44.6m / Avg Total Assets 128.5m) |
| D: 19.87 (Book Value of Equity 126.6m / Total Liabilities 6.37m) |
| Altman-Z'' = 15.27 = AAA |
As of June 07, 2026, the stock is trading at USD 2.57 with a total of 941,535 shares traded.
Over the past week, the price has changed by -15.18%,
over one month by -23.51%,
over three months by -46.01% and
over the past year by -66.97%.
Anavex Life Sciences has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy AVXL.
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 20 | 678.2% |
P/E Forward = 3.8521
P/B = 2.225
Revenue TTM = 0.0 USD
EBIT TTM = -44.6m USD
EBITDA TTM = -44.6m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 149.0m USD (280.8m + (null Debt) - CCE 131.7m)
Interest Coverage Ratio = unknown (Ebit TTM -44.6m / Interest Expense TTM 0.0)
EV/FCF = -4.37x (Enterprise Value 149.0m / FCF TTM -34.1m)
FCF Yield = -22.86% (FCF TTM -34.1m / Enterprise Value 149.0m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 1.12 (Enterprise Value 149.0m / Total Assets 133.0m)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -35.2m (EBIT -44.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 20.87 (Total Current Assets 133.0m / Total Current Liabilities 6.37m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA -44.6m)
Debt / FCF = unknown (Net Debt none / FCF TTM -34.1m)
Total Stockholder Equity = 103.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.08% (Net Income -39.9m / Total Assets 133.0m)
RoE = -38.76% (Net Income TTM -39.9m / Total Stockholder Equity 103.1m)
RoCE = -35.22% (EBIT -44.6m / Capital Employed (Total Assets 133.0m - Current Liab 6.37m))
RoIC = -27.83% (negative operating profit) (NOPAT -35.2m / Invested Capital 126.6m)
WACC = 10.78% (E(280.8m)/V(280.8m) * Re(10.78%) + (debt-free company))
Discount Rate = 10.78% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 4.99%
[DCF] Fair Price = unknown (Cash Flow -34.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 3.09 | # QB: 3
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.08 | Chg30d=+0.00% | Revisions=+33% | Analysts=1
EPS current Year (2026-09-30): EPS=-0.33 | Chg30d=-1.54% | Revisions=+33% | GrowthEPS=+38.9% | GrowthRev=+0.0%
EPS next Year (2027-09-30): EPS=-0.55 | Chg30d=-292.86% | Revisions=-20% | GrowthEPS=-66.7% | GrowthRev=+0.0%